Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q3 2019 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
NEUROCRINE BIOSCIENCES INC | 13 | Q2 2016 | 1.9% |
GRIFOLS SA-ADR | 13 | Q2 2016 | 1.3% |
YAHOO! INC | 13 | Q2 2016 | 1.6% |
DANAHER CORP | 13 | Q2 2016 | 0.8% |
American International Group Inc | 13 | Q2 2016 | 0.7% |
ASHLAND INC | 13 | Q2 2016 | 0.4% |
B/E AEROSPACE INC | 13 | Q2 2016 | 0.3% |
HONEYWELL INTERNATIONAL INC | 13 | Q2 2016 | 0.4% |
E*TRADE FINANCIAL CORP | 13 | Q2 2016 | 0.6% |
HEALTHSOUTH CORP | 13 | Q2 2016 | 0.2% |
View Visium Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ALBANY MOLECULAR RESEARCH INCSold out | February 14, 2017 | 0 | 0.0% |
APPLIED GENETIC TECHNOLOGIES CORPSold out | February 14, 2017 | 0 | 0.0% |
AQUINOX PHARMACEUTICALS, INCSold out | February 14, 2017 | 0 | 0.0% |
Ascendis Pharma A/SSold out | February 14, 2017 | 0 | 0.0% |
ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2017 | 0 | 0.0% |
Axovant Sciences Ltd.Sold out | February 14, 2017 | 0 | 0.0% |
Bioblast Pharma Ltd.Sold out | February 14, 2017 | 0 | 0.0% |
CONMED CORPSold out | February 14, 2017 | 0 | 0.0% |
CymaBay Therapeutics, Inc.Sold out | February 14, 2017 | 0 | 0.0% |
Enzymotec Ltd.Sold out | February 14, 2017 | 0 | 0.0% |
View Visium Asset Management, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2017-02-14 |
SC 13G/A | 2017-02-14 |
SC 13G/A | 2017-02-14 |
SC 13G/A | 2017-02-14 |
SC 13G/A | 2017-02-14 |
SC 13G/A | 2017-02-14 |
SC 13G/A | 2017-02-14 |
SC 13G/A | 2017-02-14 |
SC 13G/A | 2017-02-14 |
SC 13G/A | 2017-02-14 |
View Visium Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.